Pfizer to acquire Hospira for $16B

Laura Pedulli | | Health Exec | Management

In a deal that will transform the pharmaceutical industry, Pfizer announced that it will buy rival Hospira for $16 billion, reports Wall Street Journal.

The purchase is expected to make Pfizer a leading player in the emerging market for lower-priced versions of costly biotech drugs, according to the article.

Read more below:

Pfizer to Buy Hospira for $16 Billion

Laura Pedulli

Related Content

Asante Medical facing $488M in lawsuits after fentanyl diversion linked to 16 deaths
FDA issues Class I alert on Philips ventilators after 4 injuries
Trump selects Emmy-winning TV personality Dr. Oz to head CMS
FDA issues Class I recall of infusion pump batteries due to risk of burns
Ransomware group deploys ticking clock to threaten Georgia hospital
Private equity transactions in healthcare down 15% since 2023, report finds

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”